Febuxostat

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

Retrieved on: 
Wednesday, December 14, 2022
Connective tissue, Marketing, Gout, Research, Fred Hutchinson Cancer Research Center, COVID-19, Fortress Biotech, FDA, MENA, Fortification, Drug development, Patent, Degenerative disease, City of Hope, AstraZeneca, Hospital, Regulation, URAT1, Joint, Chronic kidney disease, Patient, Heart failure, City, Urica, Tendon, Drug Quality and Security Act, Therapy, Risk, Nationwide, Pharmaceutical industry, Febuxostat, Hyperuricemia

The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.

Key Points: 
  • The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.
  • Under the terms of the agreement, the Company acquired exclusive development and marketing rights in MENA and Turkey from Fuji.
  • In May 2021, Fortress announced an exclusive license agreement between its subsidiary, Urica Therapeutics, Inc. (formerly UR-1 Therapeutics, Inc.), and Fuji Yakuhin Co. Ltd. to develop dotinurad in North America and Europe.
  • In November 2022, Urica licensed rights to dotinurad from Fuji for additional territories including MENA and Turkey.

Jacobson Pharma Announces FY2022 Annual Results

Retrieved on: 
Wednesday, June 29, 2022
Patient, Medication, Research, Marketing, COVID-19, Growth, Pramipexole, Company, Tax, JBM, Febuxostat, Guangdong-Hong Kong-Macau Greater Bay Area, Vaccination, Acceleration, Development, Department, Depreciation, EBITDA, Big White Duel, GMP, Acute promyelocytic leukemia, Idarubicin, Department of Health (Hong Kong), Fosun International, Fosun Pharma, Diabetes, Medical device, Conditional sentence, Greater, Dexmedetomidine, Health care, Public sector, Hospital, Board, PIC/S, HK, Analgesic, Sale, Amlodipine, The Group, University, Cardiovascular disease, Tablet, Immunity, Generic drug, Pharmaceutical industry, Vaccine, Valsartan, Group, Vaccine, Telmisartan, Brimonidine

HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Retrieved on: 
Tuesday, May 31, 2022
Gout, Chronic kidney disease, Hyperuricemia, Risk, Hospital, Private Securities Litigation Reform Act, Joint, URAT1, Patient, NASDAQ, Therapy, Pharmacokinetics, Degenerative disease, Fred Hutchinson Cancer Research Center, COVID-19, Nationwide, Uric acid, City, FDA, Research, Patent, Securities Act of 1933, Securities Exchange Act of 1934, City of Hope, Forward-looking statement, Safety, Heart failure, Connective tissue, Drug Quality and Security Act, Drug development, Fortress Biotech, Regulation, Tendon, SEC, Fortification, AstraZeneca, GLOBE, Pharmaceutical industry, Febuxostat

MIAMI, May 31, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that its subsidiary company, UR-1 Therapeutics, Inc. (“UR-1”), dosed the first patient in a Phase 1 clinical trial evaluating Dotinurad for the treatment of gout in the United States.

Key Points: 
  • The principal objective of this Phase 1 clinical trial is to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of Dotinurad in Western subjects.
  • Subjects will be randomized into a placebo-controlled crossover clinical trial design to evaluate a wide range of Dotinurad doses.
  • Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.
  • Dotinurad has been approved to treat gout and hyperuricemia in Japan and is currently in a Phase 1 clinical trial in the United States.

Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout

Retrieved on: 
Monday, March 21, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Urine, Risk, Obesity, Allopurinol, SUA, Therapy, Fatty liver disease, List of life sciences, University of Alabama, Hepatotoxicity, Chugai Pharmaceutical Co., Kidney, Gout, Uric acid, Tenderness, Nephrotoxicity, Cardiovascular disease, Pain, Joint, Febuxostat, NASH, Safety, Red, Diabetes, Medication, American College, Time, Inflammatory arthritis, Lists of diseases, Sudden death, Degenerative disease, URAT1, American College of Rheumatology, Swelling, FDA, Blood, Division, University, Patient, Pharmaceutical industry, Copper, Hyperuricemia, Rheumatology

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout.
  • These results demonstrate that ABP-671, our investigational drug for the treatment of gout, lowers uric acid levels considerably, which is a major step forward for the control of chronic gout.
  • I am very excited by these results, said Atom CEO, Chairman, and Founder Dr. William Shi.
  • The poor efficacy and safety profiles of available gout drugs creates significant unmet clinical demand for patients suffering from chronic gout.

Tumor Lysis Syndrome (TLS) Market Spotlight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022
Health, Oncology, Burkitt lymphoma, Incidence, Sanofi, Acute leukemia, Probability, Tumor lysis syndrome, Acute myeloid leukemia, TLS, Febuxostat, Pharmaceutical industry, Allopurinol

The "Market Spotlight: Tumor Lysis Syndrome (TLS)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Tumor Lysis Syndrome (TLS)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
  • The publisher estimates that in 2017, there were approximately 12,400 incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt's lymphoma)
    The number of incident cases is forecast to increase to 13,600 by 2026.
  • Sanofi has carried out the most clinical trials in the TLS space, with Menarini being the only other trial sponsor.

Jacobson Pharma Announces FY2022 Interim Results

Retrieved on: 
Friday, November 26, 2021
Private, Federation of Public and Private Sector Employees, Health care, Company, Public, Central nervous system, Tablet, Vaccination, ADHD, Marketing, Conditional sentence, Board, Febuxostat, CNS, Department, Department of Health (Hong Kong), GMP, Public Sector Marketing, JBM, Health, D, Research, Private sector development, II, Public sector, Sale, Population, The Group, Growth, Canopy Growth, Patient, Ageing, Psoriasis, HK, EBITDA, Depreciation, Prevalence, Group, PIC/S, COVID-19, Haloperidol, Idarubicin, Tax, Private sector, Fine chemical, Pharmaceutical industry

The Board has resolved to declare an increased interim dividend by 50% to HK1.2 cents per share for the six months ended 30 September 2021 (FY2021 Interim: HK0.8 cent).

Key Points: 
  • The Board has resolved to declare an increased interim dividend by 50% to HK1.2 cents per share for the six months ended 30 September 2021 (FY2021 Interim: HK0.8 cent).
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated with the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2021 ACN Newswire .

Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market

Retrieved on: 
Monday, January 11, 2021
Biotechnology, FDA, Pharmaceutical, Health, Companies, Chemical compounds, Pharmaceutical companies, Febuxostat, Nitriles, Thiazoles, NIFTY 50, Dr. Reddy's Laboratories, IQVIA, Medication

Consider the risks and benefits of Febuxostat when deciding to prescribe or continue patients on Febuxostat.

Key Points: 
  • Consider the risks and benefits of Febuxostat when deciding to prescribe or continue patients on Febuxostat.
  • *IQVIA Retail and Non-Retail MAT October 2020.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Novadoz Pharmaceuticals/MSN Labs is granted FDA Approval of generic Febuxostat Tablets, begins immediate shipping

Retrieved on: 
Monday, December 30, 2019
Health, Pharmaceuticals policy, Articles, Chemical compounds, Febuxostat, Nitriles, Thiazoles, Generic drug, Pharmaceutical industry in China, Food and Drug Administration

PISCATAWAY, N.J., Dec. 30, 2019 /PRNewswire/ -- Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, based in Hyderabad India, has received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets.

Key Points: 
  • PISCATAWAY, N.J., Dec. 30, 2019 /PRNewswire/ -- Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, based in Hyderabad India, has received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets.
  • Seshu Akula, Novadoz President North America Generics, states, "FDA approval of Febuxostat is the 12th product introduction for the Novadoz label in the first 20 months of our U.S commercialization.
  • The FDA approval of Febuxostat furthers our emergence as a future leader in the generic pharma industry."
  • Additionally, the company also manufactures oral solids, liquids, and specialty injectable products in sixty-five markets throughout the world, doing business in the U.S as Novadoz Pharmaceuticals.